KR20200013449A - Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof - Google Patents
Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof Download PDFInfo
- Publication number
- KR20200013449A KR20200013449A KR1020180088663A KR20180088663A KR20200013449A KR 20200013449 A KR20200013449 A KR 20200013449A KR 1020180088663 A KR1020180088663 A KR 1020180088663A KR 20180088663 A KR20180088663 A KR 20180088663A KR 20200013449 A KR20200013449 A KR 20200013449A
- Authority
- KR
- South Korea
- Prior art keywords
- polyurethane foam
- polyurethane
- antimicrobial
- activated carbon
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A61F13/00017—
-
- A61F13/00029—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
- A61F2013/0074—Plasters means for wound humidity control with absorbing pads containing foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
본 발명은 창상, 화상 등의 상처부위를 보호하면 상처 치유를 도와주는 항균성 폴리우레탄 폼 드레싱재에 관한 것으로, 특히 항균 성분으로 은-활성탄 복합체를 함유하는 폴리우레탄 폼 드레싱재 및 그 제조방법에 관한 것이다. 본 발명에서는, 활성탄을 질산은 용액에 함침한 후 불활성 기체 하에서 열처리하여 얻은 은-활성탄 복합체를 항균 유효성분으로 함유하는 미세다공성의 폴리우레탄 폼층과; 상기 폼층의 상면에 부착되고 투습방수성인 폴리우레탄 필름층과; 상기 폼층의 하면에 부착되고 상처면과 접촉하게 되는 천공된 폴리우레탄 필름층을 포함하는, 항균성 폴리우레탄 폼 드레싱재를 제공한다. 본 발명의 드레싱재에서는 항균성 은 입자가 다공성인 활성탄과 미세다공성인 폼층의 이중 구조 내에 안정적으로 분포해 있게 되므로, 상처에 적용 시 항균성 은 입자의 방출이 삼출물의 양에 크게 좌우되지 않고 소량의 삼출물이나 다량의 삼출물 모두에서 지속적이고 안정적으로 방출이 이루어지게 된다. The present invention relates to an antimicrobial polyurethane foam dressing material that helps to heal wounds by protecting wounds such as wounds and burns. In particular, the present invention relates to a polyurethane foam dressing material containing a silver-activated carbon composite as an antimicrobial component and a method of manufacturing the same. will be. In the present invention, the microporous polyurethane foam layer containing a silver-activated carbon composite obtained by impregnating the activated carbon in the silver nitrate solution and heat treatment under an inert gas as an antimicrobial active ingredient; A polyurethane film layer attached to an upper surface of the foam layer and waterproof against moisture; An antimicrobial polyurethane foam dressing material is provided that includes a perforated polyurethane film layer attached to a lower surface of the foam layer and in contact with a wound surface. In the dressing material of the present invention, since the antimicrobial silver particles are stably distributed in the dual structure of the porous activated carbon and the microporous foam layer, the release of the antimicrobial silver particles when applied to the wound does not depend greatly on the amount of exudate, but a small amount of exudate. However, sustained and stable release is achieved for both large quantities of exudate.
Description
본 발명은 창상, 화상 등의 상처부위를 보호하면서 상처 치유를 도와주는 항균성 폴리우레탄 폼 드레싱재에 관한 것으로, 특히 항균 성분으로 은-활성탄 복합체를 함유하는 폴리우레탄 폼 드레싱재 및 그 제조방법에 관한 것이다. The present invention relates to an antimicrobial polyurethane foam dressing material that helps to heal wounds while protecting wounds such as wounds and burns. In particular, the present invention relates to a polyurethane foam dressing material containing a silver-activated carbon composite as an antimicrobial component and a method of manufacturing the same. will be.
1970년대 초 로비(Rovee)는 습윤 환경을 유지하여 가피를 형성하지 않는 환경을 만드는 것이 상피세포를 창상부로 이동시키고 상피재생을 촉진시킨다는 연구결과를 발표하였다. 이후 개방된 창상의 경우는 상피세포의 이동이 가피층에서 형성되는 콜라겐에 의해 억압되고 창상부액이 혈관신생과 상피화를 자극하는 여러 종류의 성장인자(growth factor)를 없애게 된다는 연구 결과가 나와 이 이론을 뒷받침하였다.In the early 1970's, Rovee published a study stating that creating a non-crusted environment by maintaining a humid environment would move epithelial cells to the wound and promote epithelial regeneration. In the case of open wounds, research suggests that epithelial cell migration is suppressed by collagen formed in the epidermal layer, and that the wound fluid eliminates various growth factors that stimulate angiogenesis and epithelialization. Supported the theory.
이와 같이 습윤 환경은 재생 상피세포가 상처면을 따라 원활하게 전개할 수 있도록 도움을 주지만 건조한 환경에서는 상처면을 따라 전개하지 못하기 때문에 창상의 복원이 늦어지고 창상의 치유가 비효율적으로 진행된다. 또한 삼출액에 포함되어 있는 여러 가지 상처 치유에 관여하는 물질들이 습윤 환경 하에서는 원활히 그 역할을 수행할 수 있기 때문에 상처 치유가 효율적으로 진행된다.As such, the moist environment helps the regenerated epithelial cells to develop smoothly along the wound surface, but in a dry environment, the wound cannot be deployed along the wound surface, resulting in slow recovery of the wound and inefficient healing of the wound. In addition, because the substances involved in various wound healing contained in the exudates can play a role in a wet environment smoothly, wound healing proceeds efficiently.
상처치유에 관여하는 주요 인자로는 크게 습윤 환경(humidity), 온도(temperature), 감염(infection), 산소농도(oxygen) 등을 들 수 있다. 이상적인 드레싱재는 상처와 드레싱재 사이의 습윤환경을 유지하고, 적절한 흡수성 및 투습성이 있어야 하며, 상처면의 건조를 막고 주변 정상 피부의 침연(짓무름)이 일어나지 않아야 한다. 또한 가스의 교환, 외부로부터의 세균침입 방지 등의 기능성을 갖고, 교환 시 신생조직 등에 손상을 입히지 않도록 상처면에 달라붙지 않아야 한다. Major factors involved in wound healing include wetness (humidity), temperature, infection (infection), oxygen concentration (oxygen). The ideal dressing material should maintain a wetting environment between the wound and the dressing material, be adequately absorbent and moisture permeable, prevent drying of the wound surface and avoid the swelling of the surrounding normal skin. In addition, it has the functions of gas exchange, prevention of bacterial invasion from the outside, and should not stick to the wound surface so as not to damage new tissues during the exchange.
현재 범용적으로 사용하고 있는 습윤환경 드레싱재는 폴리우레탄 폼, 하이드로콜로이드, 하이드로겔, 반투과성 필름 드레싱재 등으로 구분할 수 있다. 이중에서도 폴리우레탄 폼은 삼출물 흡수능이 우수하고, 교환이 용이하며, 쿠션이 있어 상처의 보호기능이 뛰어나므로, 깊은 창상이나 삼출물이 다량 발생하는 창상에 주로 사용되고 있다. 그러나 삼출물 흡수능이 우수하고 습윤 환경 조성이 뛰어나더라도 감염이 되었거나 감염의 우려가 있는 창상에 적용하게 되면 2차 감염을 발생시킬 수 있는 문제점이 있다.Wetting environment dressing materials that are currently used universally can be divided into polyurethane foam, hydrocolloid, hydrogel, semi-permeable film dressings and the like. Polyurethane foam is excellent in absorbing exudates, easily exchanged, and cushioned to provide excellent protection against wounds. Therefore, polyurethane foam is mainly used for wounds in which deep wounds and exudates are generated. However, even if the exudation ability is excellent and the composition of the wet environment is excellent, there is a problem that can cause a secondary infection when applied to a wound or a wound that may be infected.
감염은 창상치유에 있어서 직접적인 영향을 미치는 인자로서 세균을 다수 포함하는 조직에서는 상피 세포의 이동이 원활하지 못하고 염증이 장기간 지속되면서 치유가 지연되게 된다. 또한, 감염은 드레싱 교환 시나 처치 시 주의를 기울이지 않거나 오염된 부위를 완전히 소독하지 못하고 처치할 경우에도 발생할 수 있는 부작용이다.Infection is a factor directly affecting wound healing. In tissue containing a large number of bacteria, epithelial cell migration is not smooth and inflammation is prolonged and the healing is delayed. In addition, infection is a side effect that may occur when care is taken during dressing change or treatment, or when the contaminated area is not completely disinfected.
이러한 감염 문제점을 해결하기 위하여, 대한민국 등록특허 제10-1377569호에서는 항균성 창상피복재 및 그 제조방법을 개시하고 있고, 대한민국 공개특허 제10-2016-0035129호에서는 항균물질의 서방용 창상 피복 조성물 및 창상피복재의 제조방법을 개시하고 있다. 또한, 필름 종류에 따라 약물 방출 속도가 다른 드레싱재도 개발되었다.In order to solve such an infection problem, Korean Patent No. 10-1377569 discloses an antimicrobial wound coating material and a manufacturing method thereof, and Korean Patent Publication No. 10-2016-0035129 discloses a slow release wound coating composition and wound of an antimicrobial material. Disclosed is a method for producing a coating material. In addition, dressing materials having different drug release rates according to film types have also been developed.
그러나 종래의 약물이 함유된 폴리우레탄 폼 드레싱재의 경우 약물방출 조절이 쉽지 않아 과도하게 약물이 방출될 경우에는 약물의 낭비와 피부자극의 우려가 있고, 삼출물이 적은 경우에는 방출이 원활하지 않아 약효를 제대로 나타내기 어려운 문제가 있다. However, in the case of the polyurethane foam dressing material containing the conventional drug, it is not easy to control drug release, and when the drug is released excessively, there is a risk of drug waste and skin irritation, and when there is little exudation, the drug is not released smoothly. There is a problem that is difficult to represent properly.
본 발명은 상기와 같은 종래의 항균성 드레싱재의 문제점을 해결하기 위한 것으로, 본 발명에서는 항균 성분으로 기존 항균성 약물 대신 자체 개발한 은-활성탄 복합체를 폴리우레탄 폼 드레싱재에 적용한다. 특히, 본 발명에서는 미세다공성의 폼층을 중심으로 상부에는 투습방수성인 폴리우레탄 필름층이, 하부에는 천공된 폴리우레탄 필름층이 있는 드레징재의 가운데 폼층에 은-활성탄 복합체를 함유시킴으로써 삼출물의 양이나 창상의 환경에 크게 영향 받지 않고 항균성 은의 용출을 적절하게 유지하면서 지속적으로 항균효과를 나타낼 수 있는 항균성 폴리우레탄 폼 드레싱재를 제공하는 것을 목적으로 한다. The present invention is to solve the problems of the conventional antimicrobial dressings as described above, in the present invention, instead of the existing antimicrobial drug as an antimicrobial component, the self-developed silver activated carbon composite is applied to the polyurethane foam dressings. Particularly, in the present invention, the amount of exudates is contained by containing a silver-activated carbon composite material in the middle of the dressing material having a moisture-permeable waterproof polyurethane film layer at the top, and a perforated polyurethane film layer at the bottom, centering on the microporous foam layer. An object of the present invention is to provide an antimicrobial polyurethane foam dressing material capable of continuously exhibiting an antimicrobial effect while maintaining the elution of antimicrobial silver appropriately without being greatly affected by the wound environment.
상기 목적을 달성하기 위하여, 본 발명에서는, In order to achieve the above object, in the present invention,
활성탄을 질산은 용액에 함침한 후 불활성 기체 하에서 열처리하여 얻은 은-활성탄 복합체를 항균 유효성분으로 함유하는 미세다공성의 폴리우레탄 폼층과; A microporous polyurethane foam layer containing a silver-activated carbon composite obtained by impregnating activated carbon with a silver nitrate solution and heat-treated under an inert gas as an antimicrobial active ingredient;
상기 폼층의 상면에 부착되고 투습방수성인 폴리우레탄 필름층과; A polyurethane film layer attached to an upper surface of the foam layer and waterproof against moisture;
상기 폼층의 하면에 부착되고 상처면과 접촉하게 되는 천공된 폴리우레탄 필름층을 포함하는, 항균성 폴리우레탄 폼 드레싱재를 제공한다.An antimicrobial polyurethane foam dressing material is provided that includes a perforated polyurethane film layer attached to a lower surface of the foam layer and in contact with a wound surface.
상기 은-활성탄 복합체는 활성탄을 1~20mol/L 농도의 질산은 용액에 함침한 후 불활성 기체 하에서 100~500℃로 10분~8시간 열처리하여 얻은 것임이 바람직하다. The silver-activated carbon composite is preferably obtained by impregnating activated carbon in a silver nitrate solution having a concentration of 1 to 20 mol / L, and then performing heat treatment at 100 to 500 ° C. for 10 minutes to 8 hours under an inert gas.
상기 불활성 기체는 수소와 질소의 혼합기체인 것이 바람직하다.remind The inert gas is preferably a mixed gas of hydrogen and nitrogen.
상기 폴리우레탄 폼층은, 바람직하게는 폴리우레탄 프리폴리머 100중량부와 발포조성물 30~150중량부를 혼합한 발포 혼합액을 일정 두께로 도포하여 발포 성형시켜 얻으며, 바람직하게는 두께가 1~15mm이다. The polyurethane foam layer is preferably obtained by applying a foamed mixture mixture of 100 parts by weight of the polyurethane prepolymer and 30 to 150 parts by weight of the foamed composition by applying a predetermined thickness to foam molding, and preferably having a thickness of 1 to 15 mm.
상기 발포조성물은 물과 가교제를 포함하고 조성물 전체 중량 중 0.01~8중량%로 은-활성탄 복합체를 포함한다. The foamed composition includes water and a crosslinking agent and comprises a silver-activated carbon composite in an amount of 0.01 to 8% by weight based on the total weight of the composition.
또한, 본 발명에서는, In the present invention,
(a) 물과 가교제를 포함하고 동시에 전체 중량 중 0.01~8중량%로 은-활성탄 복합체를 포함시켜 발포조성물을 만드는 단계;(a) preparing a foamed composition comprising water and a crosslinking agent and at the same time including a silver-activated carbon composite at 0.01 to 8% by weight of the total weight;
(b) 폴리우레탄 프리폴리머 100중량부와 상기 발포조성물 30~150중량부를 혼합하여 발포 혼합액을 만드는 단계;(b) mixing 100 parts by weight of the polyurethane prepolymer and 30 to 150 parts by weight of the foam composition to form a foam mixture;
(c) 상기 발포 혼합액을 이형지 위에 일정 두께로 도포하고 발포 성형시켜 미세다공성의 항균성 폴리우레탄 폼층을 형성하는 단계;(c) applying the foam mixture to a predetermined thickness on a release paper and foam molding to form a microporous antimicrobial polyurethane foam layer;
(d) 주사슬에 친수기가 도입된 폴리우레탄 수지에 용매를 가하고 교반한 다음 이형지에 도포한 후 건조시켜 무공형의 투습방수성 폴리우레탄 필름층을 만드는 단계;(d) adding a solvent to the polyurethane resin into which the hydrophilic group is introduced into the main chain, stirring and applying to a release paper, followed by drying to form a non-porous moisture-permeable polyurethane film layer;
(e) 상기 (d) 단계와 동일하게 무공형의 투습방수성 폴리우레탄 필름층을 얻은 후, 관통공이 형성되도록 천공시켜 천공된 폴리우레탄 필름층을 만드는 단계; 그리고(e) obtaining a non-porous moisture-permeable polyurethane film layer in the same manner as in step (d), and then forming a perforated polyurethane film layer by perforating through-holes to be formed; And
(f) 상기 ((c) 단계에서 얻은 폴리우레탄 폼층이 완전히 경화하기 전에 택성이 있는 상태에서 상부에는 (d) 단계에서 얻은 폴리우레탄 필름층을, 하부에는 (e) 단계에서 얻은 천공된 폴리우레탄 필름층을 놓고 합지하는 단계를 포함하는, 항균성 폴리우레탄 폼 드레싱재의 제조방법을 제공한다. (f) the polyurethane film layer obtained in step (d) in the upper part and the perforated polyurethane obtained in step (e) in the upper part with a tack before the polyurethane foam layer obtained in step (c) is completely cured. It provides a method for producing an antimicrobial polyurethane foam dressing material, comprising the step of laminating a film layer.
본 발명의 폴리우레탄 폼 드레싱재는 활성탄을 질산은 용액에 함침한 후 불활성 기체 하에서 열처리하여 얻은 '은-활성탄 복합체'를 항균 유효성분으로 가운데 폼층에 함유함으로써, 항균성 은 입자가 다공성인 활성탄과 미세다공성인 폼층의 이중 구조 내에 안정적으로 분포해 있게 되며, 그 결과 상처에 적용 시 항균성 은 입자의 방출이 삼출물의 양에 크게 좌우되지 않고, 소량의 삼출물이나 다량의 삼출물 모두에서 방출이 지속적이고 안정적으로 이루어지게 된다. 본 발명의 폼 드레싱재는 일정하게 항균성을 유지하면서 지속시간이 길어지고 소취기능 또한 있어 균에 의해 발생하는 냄새를 제거할 수 있으며, 부착감이 좋고 치수변화율이 적다. 또한, 약물을 함유하는 폴리우레탄 폼층의 성형 시 상부의 폴리우레탄 필름층과 하부의 천공된 폴리우레탄 필름층을 그대로 적층하여 합지함으로써 생산 효율과 생산성이 높아진다. The polyurethane foam dressing material of the present invention contains the 'silver-activated carbon composite material' obtained by impregnating activated carbon in a silver nitrate solution and heat-treated under an inert gas as an antimicrobial active ingredient in the middle foam layer, whereby the antimicrobial silver particles are porous and microporous. This results in a stable distribution within the dual structure of the foam layer, which results in the release of antimicrobial silver particles upon application to the wound, without causing much dependence on the amount of exudate, and for sustained and stable release in both small and large amounts of exudate. do. Foam dressing material of the present invention, while maintaining a constant antimicrobial and long duration and deodorizing function can also remove the odor caused by the bacteria, good adhesion and less dimensional change rate. In addition, when forming a polyurethane foam layer containing a drug by laminating and laminating the upper polyurethane film layer and the lower perforated polyurethane film layer as it is, the production efficiency and productivity is increased.
도 1은 본 발명의 항균성 폴리우레탄 폼 드레싱재의 모식도이다.
도 2는 본 발명의 드레싱재의 제조 공정 모식도이다.1 is a schematic diagram of the antimicrobial polyurethane foam dressing material of the present invention.
It is a schematic diagram of the manufacturing process of the dressing material of this invention.
본 발명의 항균성 폴리우레탄 폼 드레싱재는, 은-활성탄 복합체를 항균 유효성분으로 함유하는 미세다공성의 폴리우레탄 폼층과; 상기 폼층의 상면에 부착되고 투습방수성인 폴리우레탄 필름층과; 상기 폼층의 하면에 부착되고 상처면과 접촉하게 되는 천공된 폴리우레탄 필름층을 포함한다. 도 1은 본 발명의 항균성 폴리우레탄 폼 드레싱재의 모식도이다. The antimicrobial polyurethane foam dressing material of the present invention comprises a microporous polyurethane foam layer containing a silver-activated carbon composite as an antimicrobial active ingredient; A polyurethane film layer attached to an upper surface of the foam layer and waterproof against moisture; And a perforated polyurethane film layer attached to the bottom surface of the foam layer and in contact with the wound surface. 1 is a schematic view of the antimicrobial polyurethane foam dressing material of the present invention.
이하 항균성 폴리우레탄 폼 드레싱재의 구성을 보다 상세하게 설명한다.Hereinafter, the configuration of the antimicrobial polyurethane foam dressing material will be described in more detail.
상기 폴리우레탄 폼층(20)은 미세다공성으로 형성되며, 항균 유효성분으로 은-활성탄 복합체를 함유한다. 본 발명에서는 '은-활성탄 복합체'와 동일한 의미로 '항균성 탄소복합체'라는 용어도 사용된다. The
은-활성탄 복합체는 활성탄을 질산은 용액에 함침한 후 불활성 기체 하에서 열처리하여 얻은 것이다. 은-활성탄 복합체는 바람직하게는 활성탄을 1~20mol/L 농도의 질산은 용액에 함침한 후 불활성 기체 하에서 100~500℃로 10분~8시간 열처리하여 얻는다. 보다 바람직하게는 상기 불활성 기체는 수소와 질소의 혼합기체이며, 특히 바람직하게는 수소와 질소가 각각 50부피%씩 혼합된 혼합기체이다. The silver-activated carbon composite material is obtained by impregnating activated carbon in a silver nitrate solution and then heat-treating it under inert gas. The silver-activated carbon composite is preferably obtained by impregnating activated carbon in a silver nitrate solution at a concentration of 1 to 20 mol / L, and then heat-treating at 100 to 500 ° C. for 10 minutes to 8 hours under an inert gas. More preferably, the inert gas is a mixed gas of hydrogen and nitrogen, and particularly preferably a mixed gas of 50% by volume of hydrogen and nitrogen.
상기 열처리 후에 얻어진 은-활성탄 복합체는, 분말상이며, 은 입자가 다공성인 활성탄의 기공을 포함한 넓은 표면적에 균일하게 안정적으로 분포되어 있다. 항균성을 지닌 은 입자가 활성탄의 넓은 표면에 안정적으로 존재하고, 이러한 은-활성탄 복합체가 다시 미세다공성인 폼층의 기공 내에 안정적으로 분포해 있게 된다. 따라서 항균성 은 입자는 이러한 이중 구조 내에 안정적으로 존재하게 되므로, 드레싱재가 상처에 적용되면, 소량의 삼출물만 있어도 삼출물이 폼층으로 유입되어 머물면서 은-활성탄 복합체와 접촉되어 서서히 은 입자를 방출시키게 된다. 또한 삼출물이 많은 경우에도 폼 층에서 은-활성탄 복합체와 접촉되는 삼출물의 면적에는 큰 차이가 없므으로 역시 균일한 속도로 서서히 은 입자를 방출시키게 된다. 이렇게 본 발명의 드레싱재에서는 은 입자가 고온 처리된 활성탄과 폼층이라는 이중 구조 내에 안정적으로 분포하게 되므로 삼출물이 적거나 많은 경우 모두 은 입자의 방출이 일정한 속도로 균일하고 안정적으로 이루어지게 된다. The silver-activated carbon composite material obtained after the heat treatment is uniformly and stably distributed over a large surface area including pores of activated carbon in which the silver particles are porous. Silver particles having antimicrobial stability are stably present on a wide surface of activated carbon, and these silver-activated carbon composites are stably distributed in the pores of the foam layer which is microporous again. Therefore, since the antimicrobial silver particles are stably present in the dual structure, when the dressing material is applied to the wound, even if only a small amount of exudate is exuded into the foam layer, the exudate stays in contact with the silver-activated carbon composite to gradually release the silver particles. In addition, even in the case of a large amount of exudate, there is no significant difference in the area of the exudate in contact with the silver-activated carbon composite in the foam layer, which also gradually releases silver particles at a uniform rate. Thus, in the dressing material of the present invention, since the silver particles are stably distributed in the dual structure of the activated carbon and the foam layer subjected to the high temperature treatment, the ejection of the silver particles is uniformly and stably made at a constant rate in all cases where the exudates are small or many.
폼층은, 폴리우레탄 프리폴리머 100중량부와 발포조성물 30~150중량부를 혼합한 발포 혼합액을 일정 두께로 도포하여 발포 성형시켜 얻을 수 있다. 바람직하게는 폼층의 두께는 1~15mm 범위이다. 1mm 보다 얇을 경우 삼출물의 흡수능이 떨어질 수 있고, 약물의 담지능이나 방출의 균일성도 떨어지게 된다. 또한, 15mm 보다 넓을 경우 부피감으로 사용이 불편해지고, 커지는 것에 비해 삼출물의 흡수능, 약물 담지능, 방출의 균일성 면에서의 효과는 크지 않으므로 효용성이 떨어지게 된다. A foam layer can be obtained by apply | coating foaming mixture liquid which mixed 100 weight part of polyurethane prepolymers and 30-150 weight part of foaming compositions to a predetermined thickness, and foaming it. Preferably the thickness of the foam layer is in the range of 1 to 15 mm. If the thickness is less than 1mm, the absorption ability of the exudate may be reduced, and the carrying capacity of the drug or the uniformity of release may be reduced. In addition, when it is wider than 15mm, it is inconvenient to use the volume, and the effect is inferior because it is not large in terms of absorbing ability, drug carrying ability, and uniformity of release of the exudate.
폼층의 형성에 사용되는 상기 발포조성물은 바람직하게는 물, 가교제와 함께 조성물 전체 중량 중 0.01~8중량%로 은-활성탄 복합체를 포함한다. 0.01중량% 이하에서는 항균력이 떨어지게 된다. 8중량% 이상으로 사용할 경우에는 은이 항균력에 필요한 것 이상으로 과량 방출되어 낭비되고 상처에도 안 좋은 영향을 줄 수 있으며, 드레싱재의 사용 후에도 많은 양이 방출되지 않고 잔류되게 되므로 경제성이 떨어지게 된다. The foaming composition used to form the foam layer preferably comprises a silver-activated carbon composite in an amount of 0.01 to 8% by weight of the total weight of the composition together with water and a crosslinking agent. Below 0.01 wt%, the antimicrobial activity is lowered. When used in more than 8% by weight, silver is excessively released beyond what is needed for antimicrobial activity, and may adversely affect the wound, and even after the dressing material is used, a large amount is not released and remains economically inferior.
폴리우레탄 필름층(10)은 주사슬에 친수기가 도입된 폴리우레탄 수지로 형성되어 투습성과 방수성을 동시에 갖게 되며, 상기 폼층(20)의 상면에 부착된다. 폴리우레탄 필름층(10)은 드레싱재의 외측을 형성한다. The
천공된 폴리우레탄 필름층(30)은 상기 폴리우레탄 필름층(10)과 동일한 투습방수성의 폴리우레탄 필름으로 이루어지며, 천공으로 관통공이 형성된다. 천공된 된 폴리우레탄 필름층(30)은 상기 폼층(20)의 하면에 부착된다. 천공된 폴리우레탄 필름층(30)은 상처면과 접촉하게 되며, 천공되어 있어 상처로부터 드레싱재로의 삼출물의 이동이나 드레싱재로부터 상처로의 약물의 이동을 원활하게 할 수 있으며, 드레싱재가 상처면에 부착되는 것을 방지할 수 있다. The perforated
이하 본 발명의 항균성 폴리우레탄 폼 드레싱재의 제조방법을 바람직한 실시예에 의해 각 층별로 설명한다. Hereinafter, a method of manufacturing the antimicrobial polyurethane foam dressing material of the present invention will be described for each layer by preferred examples.
1. 폴리우레탄 폼층의 제조1. Preparation of polyurethane foam layer
(1) 폴리우레탄 프리폴리머의 제조(1) Preparation of Polyurethane Prepolymer
폴리올과 다이올 혼합용액에 이소시아네이트(Isocyanate)를 투입하여 반응시켜 폴리우레탄 프리폴리머를 제조한다. 폴리우레탄 프리폴리머의 구체적인 제조예는 다음과 같다. 먼저 폴리올, 다이올을 투입하여 교반 속도 150 RPM 정도로 교반하면서 50℃까지 승온시킨 후 30분 동안 교반한 다음 이소시아네이트(Isocyanate)를 투입하여 질소 분위기하에서 NCO 함량(%)이 이론치에 도달할 때까지 반응시킨다. Isocyanate is added to the polyol and diol mixed solution to react to prepare a polyurethane prepolymer. Specific preparation examples of the polyurethane prepolymer are as follows. First, polyols and diols were added, and the temperature was raised to 50 ° C. while stirring at about 150 RPM, followed by stirring for 30 minutes. Then, an isocyanate was added to react the NCO content (%) until the theoretical value was reached in a nitrogen atmosphere. Let's do it.
상기 폴리올로는 폴리프로필렌옥사이드글리콜, 폴리에틸렌옥사이드글리콜, 폴리테트라메틸렌에테르글리콜, 에틸렌옥사이드/프로필렌옥사이드 공중합체, 폴리테트라하이드로퓨란/에틸렌옥사이드 공중합체, 폴리테트라하이드로퓨란/프로필렌옥사이드 공중합체, 폴리부틸렌카보네이트글리콜, 폴리헥사메틸렌카보네이트글리콜, 폴리카프로락톤글리콜, 폴리에틸렌아디페이트, 폴리부틸렌아디페이트, 폴리네오펜틸아디페이트 및 폴리헥사메틸렌아디페이트 중에서 선택된 1종 또는 2종 이상을 혼합하여 사용한다. As the polyol, polypropylene oxide glycol, polyethylene oxide glycol, polytetramethylene ether glycol, ethylene oxide / propylene oxide copolymer, polytetrahydrofuran / ethylene oxide copolymer, polytetrahydrofuran / propylene oxide copolymer, polybutylene One or two or more selected from carbonate glycol, polyhexamethylene carbonate glycol, polycaprolactone glycol, polyethylene adipate, polybutylene adipate, poly neopentyl adipate and polyhexamethylene adipate are used in combination.
본 발명의 폴리우레탄 폼을 제조하기 위해 사용하는 폴리우레탄 프리폴리머는 친수기가 도입된 친수성 폴리우레탄 프리폴리머인 것이 바람직하다. 친수성 부여에는 친수성 그룹인 에틸렌옥사이드의 함량이 중요한데, 이는 "Journal of Cellular Plastics 1976; 12; 285" "Journal of Cellular Plastics 1983; 19; 259", 미국 특허 제4,008,189호(1975.11.4) 등에 공지된 기술을 참고로 할 수 있다. 폴리올로 2개 이상의 수산기를 갖고 분자량이 500~6,000인 에틸렌옥사이드/프로필렌옥사이드 공중합체로 에틸렌옥사이드 함량이 20~90중량%인 것을 사용하는 것이 특히 바람직하다. The polyurethane prepolymer used for producing the polyurethane foam of the present invention is preferably a hydrophilic polyurethane prepolymer having a hydrophilic group introduced therein. The content of the hydrophilic group ethylene oxide is important for imparting hydrophilicity, which is known from "Journal of Cellular Plastics 1976; 12; 285" "Journal of Cellular Plastics 1983; 19; 259", US Pat. No. 4,008,189 (1975.11.4) and the like. The technique can be referred to. As the polyol, it is particularly preferable to use an ethylene oxide / propylene oxide copolymer having two or more hydroxyl groups with a molecular weight of 500 to 6,000 with an ethylene oxide content of 20 to 90% by weight.
상기 다이올 화합물로는 에틸렌글리콜, 프로필렌글리콜, 1,3-부탄디올, 1,4-부탄디올, 1,5-펜탄디올, 1,6-헥산디올, 트리에틸렌글리콜, 디에틸렌글리콜, 테트라에틸렌글리콜, 디프로필렌글리콜, 디부틸렌글리콜, 네오펜틸글리콜, 1,4-시클로헥산디메탄올, 2-메틸-1,3-펜탄디올 등을 단독으로 또는 2종 이상 같이 사용할 수 있다. 바람직하게는 에틸렌글리콜, 프로필렌글리콜 및 1,4-부탄디올 중 선택된 1종 또는 2종 이상을 혼합하여 사용한다.Examples of the diol compound include ethylene glycol, propylene glycol, 1,3-butanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, triethylene glycol, diethylene glycol, tetraethylene glycol, Dipropylene glycol, dibutylene glycol, neopentyl glycol, 1, 4- cyclohexane dimethanol, 2-methyl-1, 3-pentanediol, etc. can be used individually or in combination of 2 or more types. Preferably, one or two or more selected from ethylene glycol, propylene glycol and 1,4-butanediol are used in combination.
상기 이소시아네이트로는 방향족, 지방족 및 치환족 이소시아네이트 또는 이들의 혼합물이 사용될 수 있다. 예를 들면, 2,4-톨루엔디이소시아네이트, 2,6-톨루엔디이소시아네이트, 메틸렌디페닐디이소시아네이트, 1,5-나프탈렌디이소시아네이트, 토리딘디이소시아네이트, 헥사메틸렌-1,6-디이소시아네이트, 이소포론디이소시아네이트, 크시렌디이소시아네이트, 시클로헥실렌-1,4-디이소시아네이트, 리신디이소시아네이트 및 테트라메틸렌-크실렌디이소시아네이트 중 선택된 1종 또는 2종 이상을 혼합하여 사용한다. 이소포론디이소시아네이트, 2,4-톨루엔디이소시아네이트, 2,6-톨루엔디이소시아네이트 또는 메틸렌디페닐이소시아네이트를 사용하는 것이 바람직하다.As the isocyanate, aromatic, aliphatic and substituted isocyanates or mixtures thereof may be used. For example, 2, 4- toluene diisocyanate, 2, 6-toluene diisocyanate, methylene diphenyl diisocyanate, 1, 5- naphthalene diisocyanate, toridine diisocyanate, hexamethylene-1, 6- diisocyanate, isophorone One or two or more selected from diisocyanate, xylene diisocyanate, cyclohexylene-1,4-diisocyanate, lysine diisocyanate and tetramethylene-xylene diisocyanate are used. Preference is given to using isophorone diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate or methylenediphenyl isocyanate.
폴리우레탄 프리폴리머의 제조 시 공지의 산화방지제를 공지된 방법에 따라 첨가할 수 있다. 산화방지제로는, 페닐-베타-나프탈아민, 시스테인염산염, 디부틸히드록시톨루엔, 노르디히드로구아자레트산, 부틸히드록시아니솔, 인산, 시트르산, 아스코르브산, 에리소르브산, 갈산프로필, Ciba Specialty Chemicals사의 IRGANOX 1010, IRGANOX 1035, IRGANOX 1076, IRGANOX 1330, IRGANOX 1425WL, IRGANOX 3114, IRGANOX B215, IRGANOX B220, IRGANOX B225, IRGANOX B561, IRGANOX B313, IRGANOX B501W, IRGANOX B900, IRGANOX B1411, IRGANOX B1412, IRGANOX PS800, IRGANOX PS802, IRGAFOS P-EPQ 등을 사용한다. 인산, 시트르산, 디부틸히드록시톨루엔, 부틸히드록시아니솔, IRGANOX 1010, IRGANOX 1035, IRGANOX 1076 및 IRGANOX 1330 중 선택된 1종 또는 2종 이상을 혼합하여 사용하는 것이 바람직하다. 산화방지제는 폴리우레탄 프리폴리머 전체 중량의 0.05~5중량% 범위에서 첨가하는 것이 바람직하다.Known antioxidants can be added according to known methods in the preparation of the polyurethane prepolymers. As antioxidant, phenyl- beta- naphthalamine, cysteine hydrochloride, dibutylhydroxytoluene, nordihydroguazaleic acid, butylhydroxyanisole, phosphoric acid, citric acid, ascorbic acid, erythorbic acid, propyl gallate, IRGANOX 1010, IRGANOX 1035, IRGANOX 1076, IRGANOX 1330, IRGANOX 1425WL, IRGANOX 3114, IRGANOX B215, IRGANOX B220, IRGANOX B225, IRGANOX B561, IRGANOX B313, IRGANOX B501W, IRGANOX IOXANOX PS800, IRGANOX PS802, IRGAFOS P-EPQ, etc. are used. It is preferable to use one or two or more selected from phosphoric acid, citric acid, dibutylhydroxytoluene, butylhydroxyanisole, IRGANOX 1010, IRGANOX 1035, IRGANOX 1076 and IRGANOX 1330. Antioxidant is preferably added in the range of 0.05 to 5% by weight of the total weight of the polyurethane prepolymer.
(2) 약물이 함유된 폴리우레탄 발포조성물의 제조(2) Preparation of Polyurethane Foam Composition Containing Drugs
물, 가교제 등을 혼합하여 발포제로 사용할 발포조성물을 제조한다. 발포조성물은 바람직하게는 탈이온수 60~120중량부, 가교제 0.5~40중량부, 계면활성제 1~10중량부를 포함하며, 동시에 발포조성물 전체 중량 중 0.01~8중량%로 은-활성탄 복합체를 포함한다. 또한, 발포조성물은 필요에 따라 전체 중량 중에 안료 0.01~2중량%, 보습제 0.01~20중량% 및 흡수보조제 0.01~40중량%를 더 포함할 수 있다.Water, a crosslinking agent and the like are mixed to prepare a foaming composition to be used as a blowing agent. The foamed composition preferably includes 60 to 120 parts by weight of deionized water, 0.5 to 40 parts by weight of crosslinking agent, and 1 to 10 parts by weight of surfactant, and at the same time contains 0.01 to 8% by weight of the silver-activated carbon composite material in the total weight of the foamed composition. . In addition, the foamed composition may further include 0.01 to 2% by weight of the pigment, 0.01 to 20% by weight of the moisturizer and 0.01 to 40% by weight of the absorbent aid, if necessary.
상기 가교제로는 글리세린, 트리메틸올프로판, 1,2,4-부탄트리올 및 솔비톨 중 선택된 1종 또는 2종 이상을 혼합하여 사용할 수 있다. 가교제는 폴리우레탄 폼 형성 시 가교 반응을 통해 폼의 기계적 물성을 향상시키는 역할을 하게 된다.As the crosslinking agent, one or two or more selected from glycerin, trimethylolpropane, 1,2,4-butanetriol and sorbitol may be mixed and used. The crosslinking agent serves to improve the mechanical properties of the foam through the crosslinking reaction when forming the polyurethane foam.
상기 계면활성제로는 공지의 계면활성제를 공지의 용도와 방법에 따라 사용할 수 있다. 예를 들어, 에틸렌옥사이드/프로필렌옥사이드 블록 공중합체인 바스프사의 F-68, F-87, F-88, F-108, F-127과, 실리콘계 계면활성제로 L-580, L-603, L-688, L-5420, SZ-1703, L-6900, L-3150, Y-7931, L-1580, L-5340, L-5333, L-6701, L-5740M, L-3002, L-626 등을 사용할 수 있다. 계면활성제는 폴리우레탄 폼 드레싱재의 기공(Pore)의 크기와 기공의 개방율을 조절하는 역할을 하게 된다. 특히 에틸렌옥사이드/프로필렌옥사이드 블록 공중합체인 바스프사의 F-68은 조직에 상해를 가하지 않고 상처를 세척하는데 도움을 주며 무독성인 것으로 알려져 있어 가장 바람직하다. As said surfactant, a well-known surfactant can be used according to a well-known use and a method. For example, BASF's F-68, F-87, F-88, F-108, and F-127, which are ethylene oxide / propylene oxide block copolymers, and L-580, L-603, L-688 as silicone-based surfactants , L-5420, SZ-1703, L-6900, L-3150, Y-7931, L-1580, L-5340, L-5333, L-6701, L-5740M, L-3002, L-626, etc. Can be used The surfactant plays a role in controlling the pore size and opening ratio of the pores of the polyurethane foam dressing material. In particular, BASF's F-68, an ethylene oxide / propylene oxide block copolymer, is most preferred because it helps to clean wounds without harming tissues and is known to be non-toxic.
본 발명에서 보습제는 상처면에 습윤환경을 유지하여 가피가 형성되는 것을 억제하고 상처치유를 원활하게 하는 역할을 한다. 따라서 본 명세서에서 '보습제'는 일반적으로 보습제로 알려져 있는 공지의 보습제는 물론 습윤환경을 유지시켜 가피 형성을 억제하고 상처치유를 원활하게 하는 상처치유보조제도 포함하는 의미로 사용된다. 이러한 보습제로는, 구체적으로 알긴산프로필렌글리콜, 메틸셀룰로오스, 카르복시메틸셀룰로오스나트륨, 카르복시메틸셀룰로오스칼슘, 카르복시메틸스타치나트륨, 알긴산나트륨, 알긴산암모늄, 알긴산칼륨, 알긴산칼슘, 카제인나트륨, 구아검, 로커스트콩검, 잔탄검, 시클로덱스트린, 아라비아검, 젤란검, 카라기난, 카라야검, 카제인, 타라검, 타마린드검, 트라가칸스검, 펙틴, 글루코만난, 가티검, 아라비노갈락탄, 퍼셀레란, 풀루란, 글구코사민, 카르복시메틸셀룰로오스, 키틴, 키토산, 소듐알지네이트, 히아루론산, 아미노산, L-아스파라긴산, L-아스파라긴산나트륨, DL-알라닌, L-이소로이신, 염산리진, 글리신, 글리세린, L-글루타민, L-글루타민산, L-글루타민산나트륨, 피리진산, L-트레오닌, 세리신, 세린, L-티로신, 헤파린, 콘드로이틴황산나트륨, 소듐알지네이트, 젤라틴 등이 상기 범위 내에서 발포혼합액에 포함될 수 있다.In the present invention, the moisturizer serves to maintain the moist environment on the wound surface to suppress the formation of the skin and to smooth the wound healing. Therefore, in the present specification, the 'humidifying agent' is used as a meaning including a well-known moisturizing agent, which is generally known as a moisturizing agent, as well as a wound healing aid that maintains a moist environment to suppress the formation of the skin and facilitate wound healing. Specific examples of such moisturizing agents include propylene glycol alginate, methyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium alginate, ammonium alginate, potassium alginate, calcium alginate, sodium casein, guar gum and locust bean gum. , Xanthan gum, cyclodextrin, arabic gum, gellan gum, carrageenan, karaya gum, casein, tara gum, tamarind gum, tragacanth gum, pectin, glucomannan, gati gum, arabinogalactan, percelanan, pullulan , Glucosamine, carboxymethyl cellulose, chitin, chitosan, sodium alginate, hyaluronic acid, amino acid, L-aspartic acid, L-aspartic acid sodium, DL-alanine, L-isoleucine, lysine hydrochloride, glycine, glycerin, L-glutamine, L- Glutamic acid, sodium L-glutamate, pyridonic acid, L-threonine, sericin, serine, L-tyrosine, heparin, sodium chondroitin sulfate, Such as rhodium alginate, gelatin may be included in the foaming mixture within this range.
또한, 상기 조성물에는 폴리우레탄 폼의 흡수성을 증가시키기 위해 공지의 고흡수성 고분자(Super Absorbent Polymer) 등의 흡수보조제가 상기 범위 내에서 포함될 수 있다. In addition, the composition may include an absorption aid such as a known super absorbent polymer (Super Absorbent Polymer) to increase the absorbency of the polyurethane foam within the above range.
또한, 안정제, 보존제, 물성 조절제 등 효능이 알려진 공지의 첨가제를 공지의 용도로 소량 첨가할 수 있다.In addition, known additives such as stabilizers, preservatives, physical property regulators, etc., which are known in potency, may be added in small amounts for known purposes.
(3) 은-활성탄 복합체의 제조(3) Preparation of Silver-Activated Carbon Composite
본 발명에서 항균 유효성분으로 사용하는 은-활성탄 복합체는 활성탄을 질산은 용액에 함침한 후 불활성 기체 하에서 열처리하여 얻는다.The silver-activated carbon composite used as an antimicrobial active ingredient in the present invention is obtained by impregnating activated carbon in a silver nitrate solution and then heat-treating it under an inert gas.
바람직하게는, 활성탄을 1~20mol/L 농도의 질산은 용액에 함침한 후 불활성 기체 하에서 100~500℃로 10분~8시간 열처리하여 얻는다. 더욱 바람직하게는, 활성탄을 질산은에 함침한 후 불활성 기체하에서 150 내지 400℃의 온도로 10분 내지 5시간 동안 열처리하여 질산은을 환원시킨 후, 얻어진 은-활성탄 복합체를 통상적인 활성탄 세척법에 따라 충분한 양의 물로 세척하여 얻는다. 상기 불활성 기체는 바람직하게는 수소와 질소의 혼합기체이며, 특히 바람직하게는 수소와 질소가 각각 50부피%씩 혼합된 혼합기체이다. Preferably, the activated carbon is obtained by impregnating a silver nitrate solution having a concentration of 1 to 20 mol / L and then heat-treating at 100 to 500 ° C. for 10 minutes to 8 hours under an inert gas. More preferably, the activated carbon is impregnated with silver nitrate and then heat treated at an inert gas at a temperature of 150 to 400 ° C. for 10 minutes to 5 hours to reduce the silver nitrate, and then the obtained silver-activated carbon composite is sufficiently prepared according to a conventional activated carbon washing method. Obtained by washing with an amount of water. The inert gas is preferably a mixed gas of hydrogen and nitrogen, and particularly preferably a mixed gas of 50% by volume of hydrogen and nitrogen.
(3) 약물이 함유된 폴리우레탄 폼층의 제조(3) Preparation of Polyurethane Foam Layer Containing Drugs
상기 폴리우레탄 프리폴리머 100중량부와 발포조성물 30~150중량부를 혼합하여 발포혼합액을 제조한다. 제조된 발포혼합액을 이형지 위에 0.05~10㎜범위의 두께로 도포하여 폼층으로 발포 성형시키며, 완전 경화되기 전의 택(Tack)성이 있는 겔(Gel) 상태로 폴리우레탄 폼층을 얻는다. 100 parts by weight of the polyurethane prepolymer and 30 to 150 parts by weight of the foamed composition are mixed to prepare a foamed mixture. The prepared foam mixture is foamed into a foam layer by applying a thickness of 0.05 to 10 mm on a release paper, and a polyurethane foam layer is obtained in a gel state with a tack property before complete curing.
먼저, 상기 단계에서 고속으로 교반된 발포 혼합액을 코팅 게이지 등을 이용하여 이형지 위에 일정한 두께로 도포한다. 그런 다음 약 1~2분의 시간이 경과하면 택성이 있는 겔 상태로 폴리우레탄 폼층이 형성된다. First, the foamed mixed solution stirred at high speed in the above step is applied to a constant thickness on a release paper using a coating gauge or the like. Then, after a time of about 1 to 2 minutes, a polyurethane foam layer is formed in a tacky gel state.
이형지로는, 특별히 한정되는 것은 아니나, 실리콘으로 처리된 이형지를 사용하는 것이 바람직하다. Although it does not specifically limit as a release paper, It is preferable to use the release paper processed with silicone.
제조된 폴리우레탄 폼층은 한정되는 것은 아니나 두께 0.1~10㎜ 범위가 바람직하며, 1.0~5.0㎜ 범위가 특히 바람직하다. The polyurethane foam layer produced is not limited, but the thickness is preferably in the range of 0.1 to 10 mm, particularly preferably in the range of 1.0 to 5.0 mm.
제조된 폴리우레탄 폼층은 건조 후 미세다공성을 갖게 된다.The polyurethane foam layer produced is microporous after drying.
2. 투습방수성 폴리우레탄 필름층의 제조2. Preparation of moisture-permeable waterproof polyurethane film layer
폴리우레탄 수지 100중량부에 메틸에틸케톤 20~70중량부, 디메틸포름아미드 5~30중량부를 가하여 교반한 다음 기포를 제거하고 이형지에 도포한 후 건조시켜 무공형의 투습방수성 폴리우레탄 필름층을 제조한다. 필요에 따라 상기 폴리우레탄 수지에 안료 1~10중량부를 더 첨가할 수 있다. 20 to 70 parts by weight of methyl ethyl ketone and 5 to 30 parts by weight of dimethylformamide were added to 100 parts by weight of the polyurethane resin, followed by stirring to remove the air bubbles, coated on a release paper, and then dried to prepare a water-proof moisture-permeable polyurethane film layer. do. As needed, 1-10 weight part of pigments can be added to the said polyurethane resin.
폴리우레탄 수지로는 투습성과 방수성을 동시에 갖는 폴리우레탄 수지, 즉 상기 폴리우레탄 폼층의 형성에 사용된 폴리우레탄 수지와 마찬가지로 주사슬에 친수기가 도입된 폴리우레탄 수지를 사용하면 투습성과 방수성을 동시에 갖는 투습방수성의 폴리우레탄 필름층을 얻을 수 있다. As the polyurethane resin, when the polyurethane resin having both moisture permeability and water resistance is used, that is, the polyurethane resin having a hydrophilic group introduced into the main chain, similarly to the polyurethane resin used to form the polyurethane foam layer, moisture permeability having moisture permeability and water resistance at the same time is used. A waterproof polyurethane film layer can be obtained.
제조된 투습방수성 폴리우레탄 필름층은 본 발명의 드레싱재의 외측을 형성하게 된다.The moisture-permeable waterproof polyurethane film layer prepared is to form the outside of the dressing material of the present invention.
제조된 투습방수성 폴리우레탄 필름층은 두께 5~100㎛ 범위가 바람직하며, 15~25㎛ 범위가 특히 바람직하다.The prepared moisture-permeable waterproof polyurethane film layer is preferably in the range of 5 to 100 μm in thickness, and particularly preferably in the range of 15 to 25 μm.
3. 천공된 폴리우레탄 필름층의 제조3. Preparation of Perforated Polyurethane Film Layer
상기의 투습방수성 폴리우레탄 필름층의 제조와 동일한 방법으로 투습방수성 폴리우레탄 필름층을 제조한 후 천공하였다. 천공은 본 출원인의 등록특허 제10-1414020호에 개시된 방법으로 수행하였다. The permeable moisture-permeable polyurethane film layer was prepared in the same manner as the preparation of the moisture-permeable waterproof polyurethane film layer, and then punched out. Perforation was performed by the method disclosed in Applicant's Patent No. 10-1414020.
4. 합지4. Lamination
상기 제조된 투습방수성 폴리우레탄 필름층, 약물이 함유된 폴리우레탄 폼층 및 천공된 폴리우레탄 필름층을 합지한다. 바람직하게는 택성이 있는 겔 상태로 얻어진 폴리우레탄 폼층의 상부에 폴리우레탄 필름층을, 폴리우레탄 폼층의 하부에 천공된 폴리우레탄 필름층을 놓고 합지한다. 도 2는 본 발명의 드레싱재의 제조 공정 모식도이다. 합지는 상부와 하부를 동시 또는 순차적으로 할 수 있다. The prepared moisture-permeable waterproof polyurethane film layer, the polyurethane foam layer containing the drug and the perforated polyurethane film layer is laminated. Preferably, the polyurethane film layer is placed on top of the polyurethane foam layer obtained in a tacky gel state, and the perforated polyurethane film layer is placed on the bottom of the polyurethane foam layer and laminated. It is a schematic diagram of the manufacturing process of the dressing material of this invention. The lamination may simultaneously or sequentially top and bottom.
합지방법으로는 일반적으로 사용되는 점착제나 접착제를 사용하는 방법, 압력을 가하는 방법 등의 공지의 방법도 사용할 수 있다. 그러나 바람직하게는 별도의 접착제나 점착제 등을 사용하지 않고 완전 경화되기 전의 택성이 있는 겔 상태의 폴리우레탄 폼층에 폴리우레탄 필름층을 놓고 그대로 합지시킨다. 이때 일정한 갭(Gap)을 두고 눌러서 폴리우레탄 폼 드레싱재의 두께를 조절한다. 합지 후 건조시키면 본 발명의 폴리우레탄 폼 드레싱재가 얻어진다.As a lamination method, well-known methods, such as the method of using the adhesive or adhesive used generally, the method of applying a pressure, can also be used. However, preferably, the polyurethane film layer is placed on the polyurethane foam layer having a tackiness before being completely cured without using any other adhesive or pressure-sensitive adhesive or the like, and then laminated as it is. At this time, by pressing a certain gap (Gap) to adjust the thickness of the polyurethane foam dressing material. Drying after lamination yields the polyurethane foam dressing material of the present invention.
이하 구체적인 실시예를 통해 본 발명을 보다 상세히 설명한다. 그러나 하기 실시예는 본 발명을 예시하는 것으로서 본 발명의 범위가 하기 실시예로 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to specific examples. However, the following examples are illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
<실시예 1><Example 1>
(1) 폴리우레탄 폼 층 제작 시 천공된 필름 직접 적용(1) Direct application of perforated film when manufacturing polyurethane foam layer
활성탄을 5mol/L 농도의 질산은 용액에 함침한 후, 부피를 기준으로 50% 수소, 50% 질소로 이루어진 불활성 기체 하에서 300℃의 온도로 1시간 열처리하여 은-활성탄 복합체를 제조하였다. 탈이온수 80g, 가교제 1.5g, 계면활성제 3g, 은-활성탄 복합체 1.5g, 안료 0.02g, 보습제 10g을 혼합하여 발포조성물을 만들었다. 프리폴리머는 등록특허 제10-0937816호의 합성예 1의 방법으로 만들었다. 프리폴리머와 발포조성물을 각각 100중량부와 70중량부로 혼합하여 발포혼합액을 제조하였다. The activated carbon was impregnated with a silver nitrate solution having a concentration of 5 mol / L, and then heat-treated at a temperature of 300 ° C. under an inert gas consisting of 50% hydrogen and 50% nitrogen based on volume for 1 hour to prepare a silver-activated carbon composite. A foaming composition was prepared by mixing 80 g of deionized water, 1.5 g of crosslinking agent, 3 g of surfactant, 1.5 g of silver-activated carbon composite, 0.02 g of pigment, and 10 g of moisturizer. The prepolymer was made by the method of Synthesis Example 1 of Patent No. 10-0937816. The prepolymer and the foamed composition were mixed to 100 parts by weight and 70 parts by weight, respectively, to prepare a foamed mixture.
투습방수성 폴리우레탄 필름층은 등록특허 제10-0937816호의 '투습방수성 폴리우레탄 필름 제조예'에 따라 만들었다. 이렇게 만들어진 투습방수성 폴리우레탄 필름을 등록특허 제10-1414020호의 방법에 따라 천공하여 천공된 폴리우레탄 필름층도 준비하였다. The moisture-permeable waterproof polyurethane film layer was made according to the 'water-permeable waterproof polyurethane film preparation example' of Patent No. 10-0937816. A permeable polyurethane film layer was also prepared by perforation according to the method of Patent No. 10-1414020.
도 2이 작업공정 모식도와 같이, 상기 제조된 발포혼합액이 도포되는 이형지에 천공된 필름을 지나가도록 하여 폴리우레탄 폼을 형성하고, 상부에 폴리우레탄 필름층을 합지하여 본 발명의 항균성 폴리우레탄 폼 드레싱재를 완성하였다. 제조된 항균성 폴리우레탄 폼 드레싱재의 단면은 도 1과 같다. Figure 2 is a working process schematic diagram, the polyurethane foam is formed by passing the perforated film on the release paper to which the prepared foam mixture is applied, and laminated a polyurethane film layer on top of the antimicrobial polyurethane foam dressing of the present invention The ash was completed. The cross section of the prepared antimicrobial polyurethane foam dressing material is shown in FIG.
<실험예 1>Experimental Example 1
물성 측정Property measurement
상기 실시예 1에서 제조된 항균성 폴리우레탄 폼 드레싱재의 물성을 다음과 같이 측정하였다.The physical properties of the antimicrobial polyurethane foam dressing material prepared in Example 1 were measured as follows.
① 삼출물 흡수도(%)① Exudation rate of exudates (%)
상기 시료들을 5cm×5cm의 크기로 취하여 상온에서 24시간 동안 방치한 후 초기무게(A)를 측정하고 24~26℃의 항온, 상대습도 40~50%의 조건에서 증류수에 24시간 동안 함침 보관한 후 꺼내어 표면의 물기를 닦아낸 후 무게(B)를 측정하였다. 최종적으로 다음 식을 이용하여 계산하였다.The samples were taken in a size of 5cm × 5cm and left for 24 hours at room temperature, and then the initial weight (A) was measured and impregnated and stored in distilled water for 24 hours at a constant temperature of 24 to 26 ° C. and a relative humidity of 40 to 50%. After taking out, wipe off the water on the surface and measured the weight (B). Finally, the following equation was used.
흡수도(%) = (B-A)/A × 100Absorbance (%) = (B-A) / A × 100
② 삼출물 보유도(%)② Retention rate of exudates (%)
상기 시료들을 5cm×5cm의 크기로 취하여 상온에서 24시간 동안 방치한 후 초기무게(A)를 측정하고 24~26℃의 항온, 상대습도 40~50%의 조건에서 증류수에 24시간 동안 함침 보관하였다. 보관 후 꺼내어 표면의 물기를 닦아낸 후 유리판 위에 펼쳐서 붙이고, 다시 36~38℃의 항온, 상대습도 40~50%의 조건의 항온 항습기에 2시간 동안 보관한 다음 무게(B)를 측정하였다. 최종적으로 다음 식을 이용하여 계산하였다.The samples were taken in a size of 5cm × 5cm and left for 24 hours at room temperature, and then the initial weight (A) was measured and impregnated and stored in distilled water for 24 hours at a constant temperature of 24 to 26 ° C. and a relative humidity of 40 to 50%. . After storage, it was taken out, wiped off the water on the surface and then spread out on a glass plate, and then again stored in a constant temperature and humidity chamber at a constant temperature of 36 ~ 38 ℃,
보유도(%) = (B-A)/A × 100Retention (%) = (B-A) / A × 100
③ 투습도③ moisture permeability
항온항습기를 이용하여 EN 13726-1에 의거하여 상기 시료들의 투습도를 측정하였으며, 이때 항온항습기의 온도는 37℃로 하였고 상대 습도는 20%로 하였다.The moisture permeability of the samples was measured in accordance with EN 13726-1 using a thermo-hygrostat, at which the temperature of the thermo-hygrostat was 37 ° C. and the relative humidity was 20%.
상기와 같이 측정된 물성을 하기 표 1에 나타내었다.Physical properties measured as described above are shown in Table 1 below.
(%)Absorbance
(%)
(%)Retention
(%)
(g/m2/day)Breathability *
(g / m 2 / day)
상기 표 1의 결과에서 알 수 있는 바와 같이, 본 발명에 따라 제조된 항균성 폴리우레탄 폼 드레싱재는 은-활성탄 복합체를 항균작용에 필요한 충분한 양으로 함유하면서도 흡수도, 보유도, 투습도 면에서 기존 드레싱재에 차이가 없는 우수한 물성을 나타냈다. As can be seen from the results of Table 1, the antimicrobial polyurethane foam dressing material prepared according to the present invention contains a silver-activated carbon composite in an amount sufficient for antimicrobial action, while existing dressing material in terms of absorbency, retention and moisture permeability. It showed excellent physical properties without any difference.
10: 폴리우레탄 필름층
20: 폴리우레탄 폼층
30: 천공된 폴리우레탄 필름층
40: 이형지10: polyurethane film layer
20: polyurethane foam layer
30: perforated polyurethane film layer
40: release paper
Claims (8)
상기 폼층의 상면에 부착되고 투습방수성인 폴리우레탄 필름층과;
상기 폼층의 하면에 부착되고 상처면과 접촉하게 되는 천공된 폴리우레탄 필름층을 포함하는, 항균성 폴리우레탄 폼 드레싱재.A microporous polyurethane foam layer containing a silver-activated carbon composite obtained by impregnating activated carbon with a silver nitrate solution and heat-treated under an inert gas as an antimicrobial active ingredient;
A polyurethane film layer attached to an upper surface of the foam layer and waterproof against moisture;
An antimicrobial polyurethane foam dressing material comprising a perforated polyurethane film layer attached to the bottom surface of the foam layer and in contact with the wound surface.
상기 은-활성탄 복합체는 활성탄을 1~20mol/L 농도의 질산은 용액에 함침한 후 불활성 기체 하에서 100~500℃로 10분~8시간 열처리하여 얻은 것임을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재. The method of claim 1,
The silver-activated carbon composite is an antimicrobial polyurethane foam dressing material, characterized in that obtained by impregnating activated carbon in a silver nitrate solution at a concentration of 1 to 20 mol / L after heat treatment at 100 to 500 ℃ for 10 minutes to 8 hours under an inert gas.
상기 불활성 기체는 수소와 질소의 혼합기체인 것을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재. The method of claim 1,
remind An inert gas is a mixed gas of hydrogen and nitrogen, characterized in that the antimicrobial polyurethane foam dressing material.
상기 폴리우레탄 폼층은, 폴리우레탄 프리폴리머 100중량부와 발포조성물 30~150중량부를 혼합한 발포 혼합액을 일정 두께로 도포하여 발포 성형시켜 얻으며,
상기 발포조성물은 물과 가교제를 포함하고 동시에 조성물 전체 중량 중 0.01~8중량%로 은-활성탄 복합체를 포함하는 것을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재. The method according to any one of claims 1 to 3,
The polyurethane foam layer is obtained by applying a foamed mixture mixture of 100 parts by weight of the polyurethane prepolymer and 30 to 150 parts by weight of the foamed composition to a predetermined thickness and foaming molding,
The foam composition comprises water and a crosslinking agent, and at the same time, characterized in that it comprises a silver-activated carbon composite at 0.01 to 8% by weight of the total weight of the composition, antimicrobial polyurethane foam dressing material.
상기 폴리우레탄 폼층은 두께가 1~15mm인 것을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재.The method of claim 4, wherein
The polyurethane foam layer is characterized in that the thickness of 1 ~ 15mm, antimicrobial polyurethane foam dressing material.
상기 폴리우레탄 폼층은 보습제를 더 포함하며,
상기 발포조성물은 조성물 전체 중량 중 0.01~20중량%로 보습제를 포함하는 것을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재. The method of claim 4, wherein
The polyurethane foam layer further comprises a moisturizer,
The foam composition is characterized in that it comprises a moisturizing agent in 0.01 to 20% by weight of the total weight of the composition, antimicrobial polyurethane foam dressing material.
상기 보습제는 알긴산프로필렌글리콜, 메틸셀룰로오스, 카르복시메틸셀룰로오스나트륨, 카르복시메틸셀룰로오스칼슘, 카르복시메틸스타치나트륨, 알긴산나트륨, 알긴산암모늄, 알긴산칼륨, 알긴산칼슘, 카제인나트륨, 구아검, 로커스트콩검, 잔탄검, 시클로덱스트린, 아라비아검, 젤란검, 카라기난, 카라야검, 카제인, 타라검, 타마린드검, 트라가칸스검, 펙틴, 글루코만난, 가티검, 아라비노갈락탄, 퍼셀레란, 풀루란, 글구코사민, 카르복시메틸셀룰로오스, 키틴, 키토산, 소듐알지네이트, 히아루론산, 아미노산, L-아스파라긴산, L-아스파라긴산나트륨, DL-알라닌, L-이소로이신, 염산리진, 글리신, 글리세린, L-글루타민, L-글루타민산, L-글루타민산나트륨, 피리진산, L-트레오닌, 세리신, 세린, L-티로신, 헤파린, 콘드로이틴황산나트륨, 소듐알지네이트, 젤라틴 중에서 선택된 1종 이상인 것을 특징으로 하는, 항균성 폴리우레탄 폼 드레싱재.The method of claim 6,
The moisturizing agent is propylene glycol alginate, methyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, sodium alginate, ammonium alginate, potassium alginate, calcium alginate, sodium caseinate, guar gum, locust bean gum, xanthan gum, Cyclodextrin, gum arabic, gellan gum, carrageenan, karaya gum, casein, tara gum, tamarind gum, tragacanth gum, pectin, glucomannan, gati gum, arabinogalactan, perseleran, pullulan, glucosamine, Carboxymethylcellulose, chitin, chitosan, sodium alginate, hyaluronic acid, amino acids, L-aspartic acid, L-aspartic acid sodium, DL-alanine, L-isoleucine, lysine hydrochloride, glycine, glycerin, L-glutamine, L-glutamic acid, L- Sodium Glutamate, Pyrizine, L-Threonine, Sericin, Serine, L-Tyrosine, Heparin, Sodium Chondroitin Sulfate, Sodium Alginate, Gel Antimicrobial polyurethane foam dressing material, characterized in that at least one selected from Latin.
(b) 폴리우레탄 프리폴리머 100중량부와 상기 발포조성물 30~150중량부를 혼합하여 발포 혼합액을 만드는 단계;
(c) 상기 발포 혼합액을 이형지 위에 일정 두께로 도포하고 발포 성형시켜 미세다공성의 항균성 폴리우레탄 폼층을 형성하는 단계;
(d) 주사슬에 친수기가 도입된 폴리우레탄 수지에 용매를 가하고 교반한 다음 이형지에 도포한 후 건조시켜 무공형의 투습방수성 폴리우레탄 필름층을 만드는 단계;
(e) 상기 (d) 단계와 동일하게 무공형의 투습방수성 폴리우레탄 필름층을 얻은 후, 관통공이 형성되도록 천공시켜 천공된 폴리우레탄 필름층을 만드는 단계; 그리고
(f) 상기 ((c) 단계에서 얻은 폴리우레탄 폼층이 완전히 경화하기 전에 택성이 있는 상태에서 상부에는 (d) 단계에서 얻은 폴리우레탄 필름층을, 하부에는 (e) 단계에서 얻은 천공된 폴리우레탄 필름층을 놓고 합지하는 단계를 포함하는, 항균성 폴리우레탄 폼 드레싱재의 제조방법. (a) preparing a foamed composition comprising water and a crosslinking agent and at the same time including a silver-activated carbon composite in an amount of 0.01 to 8% by weight based on the total weight;
(b) mixing 100 parts by weight of the polyurethane prepolymer and 30 to 150 parts by weight of the foamed composition to form a foamed mixture solution;
(c) applying the foam mixture to a certain thickness on a release paper and foam molding to form a microporous antimicrobial polyurethane foam layer;
(d) adding a solvent to the polyurethane resin into which the hydrophilic group is introduced into the main chain, stirring and applying to a release paper, followed by drying to form a non-porous moisture-permeable polyurethane film layer;
(e) obtaining a non-porous moisture-permeable polyurethane film layer in the same manner as in step (d), and then forming a perforated polyurethane film layer by perforating a through hole to be formed; And
(f) the polyurethane film layer obtained in step (d) in the upper part and the perforated polyurethane obtained in step (e) in the upper part with a tack before the polyurethane foam layer obtained in step (c) is completely cured. A method for producing an antimicrobial polyurethane foam dressing material comprising the step of laminating a film layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180088663A KR102253879B1 (en) | 2018-07-30 | 2018-07-30 | Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180088663A KR102253879B1 (en) | 2018-07-30 | 2018-07-30 | Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200013449A true KR20200013449A (en) | 2020-02-07 |
| KR102253879B1 KR102253879B1 (en) | 2021-05-20 |
Family
ID=69570230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180088663A Active KR102253879B1 (en) | 2018-07-30 | 2018-07-30 | Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102253879B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112847992A (en) * | 2020-12-31 | 2021-05-28 | 江苏汇锦然医疗器械有限公司 | Repeatedly-adhered medical foam dressing and preparation device |
| KR20210129508A (en) | 2020-04-20 | 2021-10-28 | 인제대학교 산학협력단 | Dressig agent for cavity wound treatment |
| CN113948645A (en) * | 2021-10-15 | 2022-01-18 | 吉林大学 | Perovskite battery preparation method |
| CN114907587A (en) * | 2022-04-20 | 2022-08-16 | 惠州华阳医疗器械有限公司 | Microsphere particles and preparation method thereof, polyurethane foam and preparation method thereof |
| CN115212339A (en) * | 2022-07-20 | 2022-10-21 | 浙江红雨医药用品有限公司 | Active carbon polyurethane foam dressing and preparation method thereof |
| CN116617437A (en) * | 2023-06-14 | 2023-08-22 | 海南大蟒科技有限公司 | A foam dressing containing grapefruit oil extract for antibacterial and healing promotion and preparation method thereof |
| CN117982291A (en) * | 2022-11-02 | 2024-05-07 | 安美得生医股份有限公司 | Antibacterial dressing capable of absorbing exudate in real time and method for manufacturing the same |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050073771A (en) | 2004-01-10 | 2005-07-18 | 서동호 | Porous polymer dressing form containing natural and synthetic materials |
| KR100676937B1 (en) | 2005-06-01 | 2007-02-02 | 주식회사 제닉 | Water-soluble film for skin care and wound treatment and method of manufacturing the same |
| KR20070111758A (en) | 2006-05-19 | 2007-11-22 | 주식회사 원바이오젠 | Polyurethane foam dressing material having a drug-containing layer and a method of manufacturing the same |
| KR100859626B1 (en) | 2005-11-25 | 2008-09-23 | 펭 치아 유니버시티 | Antimicrobial compositions and wound dressings |
| KR101022884B1 (en) | 2009-06-12 | 2011-03-16 | 주식회사 원바이오젠 | Polyurethane foam dressing agent comprising a drug layer and a method of manufacturing the same |
| KR101202875B1 (en) * | 2012-09-24 | 2012-11-19 | 금오공과대학교 산학협력단 | Hydrophilic polyurethane foam dressing containing mesh film and preparation method thereof |
| KR101377569B1 (en) | 2012-01-19 | 2014-03-25 | (주)시지바이오 | Antimicrobial Wound Dressing and Preparing Method of the Same |
| KR20140054331A (en) * | 2011-08-24 | 2014-05-08 | 칼곤 카본 코포레이션 | Activated carbon containing wound dressing |
| KR101414020B1 (en) | 2013-12-16 | 2014-07-02 | 김원일 | A punching method of adhesive film and punching system using it |
| KR101426740B1 (en) | 2014-02-18 | 2014-08-05 | 주식회사 원바이오젠 | Dressing containing punched adhesive film and its manufacturing method |
| US20150061171A1 (en) * | 2013-09-04 | 2015-03-05 | Bio-Medical Carbon Technology Co., Ltd. | Method of manufacturing wound dressing |
| KR20160035129A (en) | 2014-09-22 | 2016-03-31 | 주식회사 제네웰 | Composition for wound dressing and wound dressing |
| KR20180006784A (en) * | 2016-07-11 | 2018-01-19 | 금오공과대학교 산학협력단 | Cellulose based wound dressing with antimicirobial filler and manufacturing method thereof |
| KR20180075812A (en) * | 2016-12-27 | 2018-07-05 | 주식회사 원바이오젠 | Antibacterial polyurethane foam dressing and producing method thereof |
-
2018
- 2018-07-30 KR KR1020180088663A patent/KR102253879B1/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050073771A (en) | 2004-01-10 | 2005-07-18 | 서동호 | Porous polymer dressing form containing natural and synthetic materials |
| KR100676937B1 (en) | 2005-06-01 | 2007-02-02 | 주식회사 제닉 | Water-soluble film for skin care and wound treatment and method of manufacturing the same |
| KR100859626B1 (en) | 2005-11-25 | 2008-09-23 | 펭 치아 유니버시티 | Antimicrobial compositions and wound dressings |
| KR20070111758A (en) | 2006-05-19 | 2007-11-22 | 주식회사 원바이오젠 | Polyurethane foam dressing material having a drug-containing layer and a method of manufacturing the same |
| KR101022884B1 (en) | 2009-06-12 | 2011-03-16 | 주식회사 원바이오젠 | Polyurethane foam dressing agent comprising a drug layer and a method of manufacturing the same |
| KR20140054331A (en) * | 2011-08-24 | 2014-05-08 | 칼곤 카본 코포레이션 | Activated carbon containing wound dressing |
| KR101377569B1 (en) | 2012-01-19 | 2014-03-25 | (주)시지바이오 | Antimicrobial Wound Dressing and Preparing Method of the Same |
| KR101202875B1 (en) * | 2012-09-24 | 2012-11-19 | 금오공과대학교 산학협력단 | Hydrophilic polyurethane foam dressing containing mesh film and preparation method thereof |
| US20150061171A1 (en) * | 2013-09-04 | 2015-03-05 | Bio-Medical Carbon Technology Co., Ltd. | Method of manufacturing wound dressing |
| KR101414020B1 (en) | 2013-12-16 | 2014-07-02 | 김원일 | A punching method of adhesive film and punching system using it |
| KR101426740B1 (en) | 2014-02-18 | 2014-08-05 | 주식회사 원바이오젠 | Dressing containing punched adhesive film and its manufacturing method |
| KR20160035129A (en) | 2014-09-22 | 2016-03-31 | 주식회사 제네웰 | Composition for wound dressing and wound dressing |
| KR20180006784A (en) * | 2016-07-11 | 2018-01-19 | 금오공과대학교 산학협력단 | Cellulose based wound dressing with antimicirobial filler and manufacturing method thereof |
| KR20180075812A (en) * | 2016-12-27 | 2018-07-05 | 주식회사 원바이오젠 | Antibacterial polyurethane foam dressing and producing method thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210129508A (en) | 2020-04-20 | 2021-10-28 | 인제대학교 산학협력단 | Dressig agent for cavity wound treatment |
| CN112847992A (en) * | 2020-12-31 | 2021-05-28 | 江苏汇锦然医疗器械有限公司 | Repeatedly-adhered medical foam dressing and preparation device |
| CN112847992B (en) * | 2020-12-31 | 2022-08-26 | 江苏汇锦然医疗器械有限公司 | Repeatedly-adhered medical foam dressing and preparation device |
| CN113948645A (en) * | 2021-10-15 | 2022-01-18 | 吉林大学 | Perovskite battery preparation method |
| CN114907587A (en) * | 2022-04-20 | 2022-08-16 | 惠州华阳医疗器械有限公司 | Microsphere particles and preparation method thereof, polyurethane foam and preparation method thereof |
| CN115212339A (en) * | 2022-07-20 | 2022-10-21 | 浙江红雨医药用品有限公司 | Active carbon polyurethane foam dressing and preparation method thereof |
| CN117982291A (en) * | 2022-11-02 | 2024-05-07 | 安美得生医股份有限公司 | Antibacterial dressing capable of absorbing exudate in real time and method for manufacturing the same |
| CN116617437A (en) * | 2023-06-14 | 2023-08-22 | 海南大蟒科技有限公司 | A foam dressing containing grapefruit oil extract for antibacterial and healing promotion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102253879B1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102253879B1 (en) | Polyurethane foam dressing comprising silver-activated carbon composites and producing method thereof | |
| KR100937816B1 (en) | Manufacturing method of hydrophilic foam dressing material and manufactured hydrophilic foam dressing material | |
| KR101787192B1 (en) | Antimicrbacterial dressing material and method for preparing thereof | |
| KR100777908B1 (en) | Polyurethane foam dressing with improved repair rate | |
| EP1374812A1 (en) | Multilayered microporous foam dressing and method for manufacturing the same | |
| EP2393524B1 (en) | Absorbent foam wound dressing materials | |
| EP0541390A1 (en) | Wound dressing comprising polyurethane foam | |
| KR101022884B1 (en) | Polyurethane foam dressing agent comprising a drug layer and a method of manufacturing the same | |
| KR101199453B1 (en) | Method and apparatus for manufacturing continuously polyurethane foam dressing materialsm | |
| KR101648083B1 (en) | Antibacterial polyurethane foam dressing material and manufacturing method thereof | |
| WO2008156285A1 (en) | Method for producing hydrophilic foam dressing and hydrophilic foam dressing produced thereby | |
| KR101202875B1 (en) | Hydrophilic polyurethane foam dressing containing mesh film and preparation method thereof | |
| WO2007136176A1 (en) | Polyurethane foam dressing comprising drug-containing layer and method for manufacturing the same | |
| KR101811273B1 (en) | Improved Polyurethane Mask Pack and Method for Making Same | |
| US6509388B1 (en) | Polyurethane foams for use in wound dressings | |
| JP5020639B2 (en) | Medicinal polyurethane foam | |
| KR100745050B1 (en) | Manufacturing method and apparatus for polyurethane foam dressing material | |
| GB2336367A (en) | Polyurethane foams for use in wound dressings | |
| JP2993170B2 (en) | Wound dressing | |
| KR100631108B1 (en) | Wound dressing materials | |
| CA2027894C (en) | Process for preparing a sheet of polymer-based foam | |
| KR101933486B1 (en) | Antibacterial polyurethane foam dressing and producing method thereof | |
| CN115212339A (en) | Active carbon polyurethane foam dressing and preparation method thereof | |
| JP2001340375A (en) | Wound coating material | |
| KR100553078B1 (en) | 2-layer hydrophilic polyurethane foam dressing material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 6 |